Bioventus (NASDAQ:BVS – Get Free Report) and RenovoRx (NASDAQ:RNXT – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.
Earnings & Valuation
This table compares Bioventus and RenovoRx”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bioventus | $581.85 million | 1.87 | $22.73 million | $0.77 | 16.77 |
| RenovoRx | $1.12 million | 68.10 | -$11.17 million | ($0.31) | -5.45 |
Profitability
This table compares Bioventus and RenovoRx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bioventus | 9.36% | 28.08% | 9.82% |
| RenovoRx | -621.71% | -135.11% | -101.91% |
Volatility & Risk
Bioventus has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, RenovoRx has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current recommendations for Bioventus and RenovoRx, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bioventus | 0 | 1 | 5 | 0 | 2.83 |
| RenovoRx | 1 | 0 | 2 | 1 | 2.75 |
Bioventus currently has a consensus target price of $16.80, indicating a potential upside of 30.13%. RenovoRx has a consensus target price of $8.50, indicating a potential upside of 402.96%. Given RenovoRx’s higher possible upside, analysts plainly believe RenovoRx is more favorable than Bioventus.
Insider & Institutional Ownership
62.9% of Bioventus shares are held by institutional investors. Comparatively, 3.1% of RenovoRx shares are held by institutional investors. 33.5% of Bioventus shares are held by company insiders. Comparatively, 9.4% of RenovoRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Bioventus beats RenovoRx on 11 of the 15 factors compared between the two stocks.
About Bioventus
Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body’s natural healing process in the United States and internationally. The company’s portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company’s restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician’s office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
About RenovoRx
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.
